Haemonetics Corp. (NYSE:HAE)’s share price traded down 1.7% during mid-day trading on Monday . The stock traded as low as $35.01 and last traded at $35.65, with a volume of 211,653 shares changing hands. The stock had previously closed at $36.25.

Several equities analysts have recently issued reports on the company. Barrington Research decreased their price objective on Haemonetics Corp. from $40.00 to $32.00 and set an “outperform” rating for the company in a research note on Tuesday, May 3rd. Morgan Stanley restated a “hold” rating on shares of Haemonetics Corp. in a research note on Tuesday, May 3rd. BTIG Research restated a “hold” rating on shares of Haemonetics Corp. in a research note on Tuesday, April 19th. Jefferies Group boosted their target price on Haemonetics Corp. from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Finally, Zacks Investment Research cut Haemonetics Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company’s stock. Haemonetics Corp. currently has an average rating of “Hold” and a consensus price target of $33.25.

The firm’s 50 day moving average price is $31.43 and its 200 day moving average price is $31.44. The stock’s market capitalization is $1.83 billion.

Haemonetics Corp. (NYSE:HAE) last announced its quarterly earnings results on Monday, August 1st. The company reported $0.25 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.28 by $0.03. During the same period in the previous year, the company earned $0.35 EPS. The business earned $210 million during the quarter, compared to the consensus estimate of $205.41 million. Haemonetics Corp.’s revenue was down 1.6% compared to the same quarter last year. On average, equities analysts expect that Haemonetics Corp. will post $1.44 EPS for the current year.

In related news, CEO Christopher Simon bought 60,000 shares of the stock in a transaction dated Thursday, August 4th. The stock was acquired at an average price of $35.00 per share, for a total transaction of $2,100,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Other large investors recently bought and sold shares of the company. Piermont Capital Management Inc. bought a new stake in Haemonetics Corp. during the fourth quarter worth about $2,791,000. Principal Financial Group Inc. raised its stake in Haemonetics Corp. by 5.1% in the fourth quarter. Principal Financial Group Inc. now owns 344,105 shares of the company’s stock worth $11,094,000 after buying an additional 16,768 shares during the period. Rhumbline Advisers raised its stake in Haemonetics Corp. by 1.3% in the fourth quarter. Rhumbline Advisers now owns 75,509 shares of the company’s stock worth $2,434,000 after buying an additional 935 shares during the period. Finally, Comerica Bank raised its stake in Haemonetics Corp. by 0.6% in the fourth quarter. Comerica Bank now owns 52,596 shares of the company’s stock worth $1,596,000 after buying an additional 321 shares during the period.

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.